CJC-1295: The Complete Guide to Benefits, Dosing, and Research (2026)

Medici

28 Apr 2026 — 8 min read

Among the most researched and widely used growth hormone-releasing peptides, CJC-1295 has earned a reputation as a cornerstone of peptide therapy. Whether your goals are fat loss, muscle building, enhanced recovery, or anti-aging support, CJC-1295 offers a scientifically backed mechanism with a well-documented safety profile. This guide covers everything — from how it works at the molecular level to exactly how to dose it, stack it, and source it safely in 2026.

What Is CJC-1295?

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH), the naturally occurring peptide produced in the hypothalamus that signals the pituitary gland to release growth hormone (GH). The compound was originally developed by ConjuChem Biotechnologies in Canada, which sought to create a longer-acting GHRH analogue for therapeutic use.

The standard GHRH peptide (known as GHRH 1-44) is rapidly degraded in the bloodstream by the enzyme dipeptidyl aminopeptidase IV (DPP-IV), giving it a half-life of only a few minutes. CJC-1295 addresses this limitation by modifying the amino acid sequence to resist enzymatic breakdown. In its most popular form — CJC-1295 with DAC — a Drug Affinity Complex (DAC) technology allows the peptide to covalently bind to albumin, the most abundant protein in blood plasma, extending its half-life from minutes to 6–8 days.

A second, closely related compound — CJC-1295 without DAC, also known as Modified GRF 1-29 (Mod GRF 1-29) — uses only the amino acid substitutions to increase stability without albumin binding. This version has a half-life of approximately 30 minutes, producing a more natural pulsatile GH release.

Mechanism of Action

CJC-1295 acts on GHRH receptors (GHRHR) on somatotroph cells in the anterior pituitary. Once bound, it triggers a cascade of intracellular signaling:

Activation of adenylyl cyclase, increasing cyclic AMP (cAMP)
Activation of protein kinase A (PKA) phosphorylation cascades
Upregulation of growth hormone gene transcription
Pulsatile or sustained release of growth hormone from pituitary stores

The released GH then travels to the liver and peripheral tissues, stimulating production of Insulin-like Growth Factor 1 (IGF-1) — the downstream mediator responsible for most of GH's anabolic and metabolic effects.

This is a critical distinction: unlike synthetic GH injections that introduce exogenous hormone directly, CJC-1295 stimulates the pituitary's own GH release. This means it operates within the body's natural feedback systems, which many researchers consider a safer and more physiologically appropriate approach.

CJC-1295 With DAC vs. Without DAC

Understanding the difference between these two forms is essential before choosing a protocol.

CJC-1295 With DAC

Half-life: 6–8 days
GH effect: Sustained, continuous elevation — sometimes described as a "GH bleed"
Dosing frequency: 1–2 mg once or twice per week
Best for: Convenience, anti-aging, long-term GH support
Consideration: Continuous GH elevation may not mimic natural pulsatile release; some users prefer the physiological pattern of no-DAC

CJC-1295 Without DAC (Mod GRF 1-29)

Half-life: ~30 minutes
GH effect: Sharp, pulsatile spike — mirrors the body's natural GH rhythm
Dosing frequency: 100–200 mcg, 1–3 times daily
Best for: Stacking with a GHRP like Ipamorelin; muscle building and recovery goals; maximizing synergistic GH pulses
Consideration: Requires more frequent injections; timing matters

For most users interested in body composition and performance, CJC-1295 without DAC is the preferred option — particularly when stacked with Ipamorelin.

Key Benefits

1. Increased Lean Muscle Mass

By elevating GH and IGF-1, CJC-1295 enhances protein synthesis and promotes nitrogen retention. Research shows sustained IGF-1 elevation (mean 285 ng/mL vs. baseline 110 ng/mL in clinical studies) without significant changes in blood glucose or lipid markers, supporting anabolic effects with a favorable metabolic profile.

2. Fat Loss and Body Composition

GH is a potent lipolytic agent — it promotes the breakdown of stored triglycerides (lipolysis) and enhances fatty acid oxidation. Users typically report a visible reduction in visceral and subcutaneous fat over 8–12 weeks of use, often with concurrent gains in lean mass.

3. Improved Sleep Quality

The majority of natural GH is released during deep, slow-wave sleep. CJC-1295 — particularly when dosed before bed — amplifies this nocturnal pulse, leading many users to report notably deeper, more restorative sleep within the first two weeks of use.

4. Accelerated Recovery

Elevated IGF-1 levels accelerate repair of muscle tissue, connective tissue, and bone. Athletes and active individuals report faster recovery from training sessions, reduced soreness, and improved joint comfort — particularly when stacked with a healing peptide like BPC-157 or TB-500.

5. Anti-Aging and Skin Quality

Declining GH levels are a well-documented feature of aging. CJC-1295 use is associated with improvements in skin elasticity, collagen synthesis, hair quality, and overall vitality — effects consistent with restored GH/IGF-1 axis function.

6. Bone Density

IGF-1 plays a key role in osteoblast activity and bone remodeling. Sustained IGF-1 elevation may support bone mineral density — a benefit of particular interest for older users and those with osteopenia risk.

Clinical Research

The most cited human study on CJC-1295 was published in the Journal of Clinical Endocrinology & Metabolism (Teichman et al., 2006). In healthy adults aged 21–61:

A single injection of CJC-1295 produced 2- to 10-fold increases in mean plasma GH lasting 6 days or more
IGF-1 concentrations rose 1.5- to 3-fold and remained elevated for 9–11 days
Effects were dose-dependent (30 or 60 mcg/kg produced the best benefit-risk ratio)
No serious adverse events were reported
Injection site reactions occurred in ~23% of subjects and resolved within 72 hours

A subsequent 2007 study in JCEM confirmed that pulsatile GH secretion is preserved during CJC-1295 administration — meaning the pituitary's normal rhythm is not suppressed, a critical safety consideration.

It is important to note that no published human trial has evaluated continuous use beyond 90 days. Long-term safety must be extrapolated from GH physiology literature and real-world clinical experience.

Dosing Protocols

CJC-1295 With DAC — Solo Protocol

Dose: 1–2 mg subcutaneously once per week
Injection site: Abdomen, outer thigh, or deltoid
Cycle length: 12–16 weeks, followed by a 4–8 week break
Goal: Steady-state GH elevation for anti-aging, general wellness, body composition

CJC-1295 Without DAC — Solo Protocol

Dose: 100–200 mcg per injection
Frequency: 2–3 times daily (ideally morning, post-workout, and/or before bed)
Fasting window: Inject on an empty stomach — food (particularly carbohydrates) blunts GH release
Timing: At least 90 minutes after eating; wait 30–60 minutes after injection before eating

CJC-1295 + Ipamorelin Stack (Recommended)

The combination of CJC-1295 without DAC and Ipamorelin is widely considered the gold standard GH secretagogue stack. Here's why it works so well:

CJC-1295 (GHRH analogue) amplifies the magnitude of GH release
Ipamorelin (GHRP/ghrelin mimetic) triggers the timing of GH pulse and suppresses somatostatin
Together, they produce a larger, cleaner GH pulse than either peptide alone — with matched half-lives, both peak and clear simultaneously

Stack dosing protocol:

CJC-1295 (no DAC): 100 mcg per injection
Ipamorelin: 100–200 mcg per injection
Frequency: 1–3 times daily (minimum once before bed)
Both peptides can be drawn into the same insulin syringe and injected together
Cycle: 12 weeks on, 4 weeks off

Side Effects and Safety

CJC-1295 has a well-tolerated safety profile in clinical research. The most commonly reported effects include:

Injection site reactions (redness, itching, mild swelling) — most common, typically resolving in 48–72 hours
Transient flushing or warmth shortly after injection
Water retention / facial puffiness — dose-dependent; usually resolves after the first few weeks
Joint aches or tingling (carpal tunnel-like symptoms) — associated with rapid IGF-1 elevation; reduce dose if persistent
Lethargy or fatigue — most common with before-bed dosing and typically a sign the peptide is working
Hunger increase — more pronounced with GHRP stack

More serious theoretical risks from chronic GH/IGF-1 elevation include insulin resistance and effects on cell proliferation. These have not been demonstrated at therapeutic doses in clinical studies, but users with a personal or family history of hormone-sensitive conditions, diabetes, or cancer should consult a physician before use.

CJC-1295 is contraindicated during pregnancy and breastfeeding.

Legal and Regulatory Status in 2026

CJC-1295 is not FDA-approved for any therapeutic indication. In the United States, it occupies a complex regulatory position under the compounding pharmacy framework.

In 2024, the FDA removed CJC-1295 (along with Ipamorelin) from its Category 2 bulk drug substances list — the list of substances identified as presenting potential safety risks that are not eligible for routine compounding under Section 503A. This removal came after nominators withdrew the substances from Category 2 review.

In February 2026, HHS Secretary Robert F. Kennedy Jr. indicated that approximately 14 of the 19 peptides previously placed on the FDA's Category 2 list were expected to be moved to Category 1, which would allow licensed U.S. compounding pharmacies to prepare them under physician prescription. CJC-1295 is expected to be among those returned to compoundable status.

As of April 2026, CJC-1295 is in regulatory transition. Patients seeking it through U.S. compounding pharmacies should:

Work with a licensed prescribing physician
Use an accredited 503A compounding pharmacy (PCAB accreditation is a strong signal of quality)
Avoid purchasing from unregulated research chemical vendors without third-party certificates of analysis (COA)

How to Source CJC-1295 Safely

The safest and most clinically appropriate pathway to CJC-1295 in the U.S. is through a telehealth or men's/women's health clinic that specializes in peptide therapy. These clinics can:

Assess your baseline IGF-1 and GH levels via bloodwork
Issue a legitimate prescription
Connect you with a licensed 503A compounding pharmacy
Monitor your labs during the cycle

Red flags to avoid when evaluating sources:

"Research use only" labeling without third-party COAs
No independent mass spectrometry or HPLC testing
Extremely low prices (often associated with underdosing or contamination)
No cold-chain shipping for lyophilized peptides

Reconstitution and Storage

CJC-1295 is supplied as a lyophilized (freeze-dried) powder and must be reconstituted before injection:

Use bacteriostatic water (BAC water) — not sterile water, which degrades the peptide faster
Inject BAC water slowly down the side of the vial — do not shake; swirl gently
Store reconstituted vials at 2–8°C (refrigerator) and use within 28–30 days
Lyophilized (unreconstituted) peptide can be stored at room temperature for short periods but should be refrigerated or frozen for long-term storage
Never expose reconstituted CJC-1295 to temperatures above 8°C for extended periods — stability degrades rapidly

Frequently Asked Questions

How long before I see results from CJC-1295?

Most users notice improved sleep quality within 1–2 weeks. Body composition changes — fat loss and muscle gains — typically become apparent after 6–8 weeks as GH and IGF-1 levels consistently rise. Full results are usually visible by week 12.

Should I use CJC-1295 with DAC or without DAC?

For body composition goals and stacking with a GHRP like Ipamorelin, without DAC (Mod GRF 1-29) is generally preferred — the pulsatile GH release mirrors natural physiology. For convenience and steady-state GH support (especially anti-aging applications), with DAC is a valid choice.

Do I need a PCT after a CJC-1295 cycle?

Unlike anabolic steroids, CJC-1295 does not suppress the hypothalamic-pituitary-gonadal (HPG) axis and does not require post-cycle therapy (PCT). The pituitary's GH secretion returns to baseline naturally after discontinuation.

Can women use CJC-1295?

Yes. Women can benefit from CJC-1295 for fat loss, recovery, skin quality, and anti-aging. Dosing is typically at the lower end of the range. Not for use during pregnancy or breastfeeding.

Conclusion

CJC-1295 is one of the most well-studied and versatile peptides in the GH secretagogue category. Its ability to stimulate the body's own pituitary GH release — rather than introducing exogenous hormone — makes it both physiologically elegant and well-tolerated. Whether you're using the long-acting DAC form for sustained support or the pulsatile no-DAC form stacked with Ipamorelin for maximum body composition impact, the research and clinical evidence support its efficacy.

As the regulatory landscape in the U.S. continues to evolve in 2026, accessing CJC-1295 through a licensed physician and accredited compounding pharmacy remains the gold standard for safety, quality, and legality. Get your IGF-1 baseline, work with a knowledgeable clinician, and let the science work.